Mraz Amerine & Associates Inc. Sells 1,257 Shares of Core Laboratories Inc. (NYSE:CLB)

Mraz Amerine & Associates Inc. decreased its position in Core Laboratories Inc. (NYSE:CLB) by 1.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 65,249 shares of the oil and gas company’s stock after selling 1,257 shares during the quarter. Mraz Amerine & Associates Inc.’s holdings in Core Laboratories were worth $1,152,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of CLB. Envestnet Asset Management Inc. increased its position in Core Laboratories by 39.7% during the third quarter. Envestnet Asset Management Inc. now owns 328,435 shares of the oil and gas company’s stock worth $7,886,000 after acquiring an additional 93,354 shares during the period. Invesco Ltd. increased its position in Core Laboratories by 25.3% during the third quarter. Invesco Ltd. now owns 436,459 shares of the oil and gas company’s stock worth $10,479,000 after acquiring an additional 88,013 shares during the period. Deutsche Bank AG increased its position in Core Laboratories by 18.2% during the third quarter. Deutsche Bank AG now owns 27,524 shares of the oil and gas company’s stock worth $661,000 after acquiring an additional 4,247 shares during the period. Essex Investment Management Co. LLC bought a new position in Core Laboratories during the third quarter worth $1,071,000. Finally, Toroso Investments LLC increased its position in Core Laboratories by 6.9% during the third quarter. Toroso Investments LLC now owns 38,348 shares of the oil and gas company’s stock worth $921,000 after acquiring an additional 2,480 shares during the period. Institutional investors own 97.81% of the company’s stock.

Core Laboratories Price Performance

Shares of NYSE:CLB traded down $0.53 on Wednesday, hitting $16.71. The stock had a trading volume of 447,641 shares, compared to its average volume of 470,090. Core Laboratories Inc. has a twelve month low of $13.82 and a twelve month high of $27.94. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.72 and a current ratio of 2.53. The firm’s 50 day moving average price is $15.97 and its 200-day moving average price is $17.88. The company has a market capitalization of $783.03 million, a price-to-earnings ratio of 20.06, a price-to-earnings-growth ratio of 0.54 and a beta of 2.40.

Core Laboratories (NYSE:CLB) last issued its earnings results on Wednesday, January 31st. The oil and gas company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.20 by ($0.01). Core Laboratories had a net margin of 8.03% and a return on equity of 15.19%. The firm had revenue of $128.21 million during the quarter, compared to analyst estimates of $127.80 million. During the same quarter in the prior year, the firm posted $0.23 EPS. On average, equities research analysts predict that Core Laboratories Inc. will post 0.81 earnings per share for the current year.

Core Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 4th. Investors of record on Monday, February 12th were issued a $0.01 dividend. The ex-dividend date of this dividend was Friday, February 9th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.24%. Core Laboratories’s dividend payout ratio is 4.65%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. StockNews.com raised shares of Core Laboratories from a “sell” rating to a “hold” rating in a research report on Saturday, January 20th. Stifel Nicolaus dropped their target price on shares of Core Laboratories from $21.00 to $17.00 and set a “hold” rating on the stock in a research report on Monday, February 5th. Finally, Bank of America decreased their price target on shares of Core Laboratories from $17.00 to $16.00 and set an “underperform” rating on the stock in a research note on Monday. Two research analysts have rated the stock with a sell rating and three have assigned a hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $18.50.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.